CClinicalTrials.gg
RecruitingNCT05225883Updated Feb 7, 2022

GWAS in NMDAR Encephalitis

An observational study in Autoimmune Encephalitis, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2022-02-07.

Sponsored by Hospices Civils de Lyon · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2020; still recruiting 5 years 9 months later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
2,000
Sex
All
01

Study summary

Autoimmune encephalitis are characterized by the subacute development of memory deficits, altered mental status, and psychiatric symptoms, generally in association with anti-neuronal antibodies. Two main groups of autoimmune encephalitis may be distinguished based on the location of the targeted antigen: 1) Intracellular antigens, in which the antibodies are thought not to be pathogenic, and the disorders are usually strongly associated with cancer, constituting therefore paraneoplastic neurological syndromes; 2) Synaptic proteins and surface receptors, in which the antibodies are pathogenic and the frequency of cancer is variable depending on the antibody and the demographic characteristics of the patient.

Encephalitis with antibodies against N-methy-D-aspartate receptor is the most common autoimmune encephalitis, being even more frequent than infectious etiologies. It is characterized by subacute onset of memory deficits, psychiatric symptoms, speech dysfunction, seizures, movement disorders, decreased level of consciousness, dysautonomia and central hypoventilation. Nearly 50% of women with anti-NMDAR encephalitis have an ovarian teratoma, while associated tumors in elderly patients are usually carcinomas. In contrast, most cases in children and young men are non-paraneoplastic. Recently, herpes-simplex encephalitis has been described as another trigger of NMDAR encephalitis. Conversely, for the vast majority of the non-paraneoplastic autoimmune encephalitis, no acquired triggers have been described so far.

In addition to acquired susceptibility, genetic predisposition may also be important in the pathogenesis of autoimmune encephalitis. The human leukocyte antigen (HLA) is the genetic factor most frequently associated with autoimmune diseases, and it has been already linked to a few autoimmune encephalitis, such as anti-leucine rich glioma inactivated 1 (LGI1), contactin-associated protein-like 2 (CASPR2), IgLON5, and glutamic acid decarboxylase 65 (GAD65) encephalitis. However, no HLA association has been reported for NMDAR encephalitis, suggesting that in this condition, and likely in others, non-HLA loci might be involved in the pathogenesis as well.

Genome-wide association studies (GWAS) are useful tools to identify variants at genomic loci that are associated with complex diseases, and in particular, to detect associations between single-nucleotide polymorphisms (SNPs) and diseases. The aim of the study is to detect genetic variants in NMDAR encephalitis and other autoimmune encephalitis.

02

Conditions studied

  • Autoimmune Encephalitis

Keywords

  • Autoimmune Encephalitis
  • paraneoplastic neurological syndromes
  • NMDAr
03

In context

Encephalitis

283 studies on the registry are indexed under Encephalitis; 55 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 200 across 92 observational studies indexed under Encephalitis.

Browse Encephalitis studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,826 studies on the registry; 439 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with autoimmune encephalitis or paraneoplastic neurological syndromes whose samples were sent for analysis at Centre de Référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Lyon, for anti-neural antibody study and then stored at the biobank Neurobiotec.

Inclusion criteria

  • Presence of well-characterized antibodies in serum or cerebrospinal fluid;
  • Clinical picture compatible with the detected antibody based on the literature

Exclusion criteria

Exclusion Criteria:

  • Absence of complete clinicobiological data.
  • Alternative diagnosis
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Autoimmune encephalitis and paraneoplastic neurological syndromes

    Patients with well-characterized antibodies against onconeural antigens, synaptic or cell-surface antigens

    Genetic: GWAS

Interventions

  • GeneticGWAS

    This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of "good clinical practice" in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the "Centre de Ressources Biologiques des Hospices Civils de Lyon" (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study.

06

What researchers measure

Primary outcomes

  1. GWAS in autoimmune encephalitis

    Detection of genetic variants (SNPs) in autoimmune encephalitis

    Time frame: 24 month after the beginning of study

07

Study locations

1 of 1 sites recruiting
  • Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes
    Lyon, France
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05225883
Lead sponsor
Hospices Civils de Lyon
Responsible party
Sponsor
First posted
Feb 7, 2022
Start date
Dec 15, 2020
Primary completion
Dec 2023 (estimated)
Completion
Dec 2025 (estimated)
Last update
Feb 7, 2022

Study contacts

Jerome HONNORAT, MD
Contact
jerome.honnorat@chu-lyon.fr
(33) 4 72 35 78 08
Géraldine PICARD, CRA
Contact
geraldine.picard@chu-lyon.fr
33) 4 72 35 58 42

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion